![]() |
市場調查報告書
商品編碼
2176703
自主人工智慧醫療影像市場預測至2034年-全球影像模式、自主程度、臨床應用、部署模式、最終使用者和區域分析Autonomous AI Medical Imaging Interpretation Market Forecasts to 2034 - Global Analysis By Imaging Modality, Autonomy Level, Clinical Application, Deployment Mode, End User and By Geography |
||||||
根據 Stratistics MRC 的數據,預計到 2026 年,全球自主 AI 醫學影像市場規模將達到 28 億美元,並在預測期內以 17.7% 的複合年成長率成長,到 2034 年將達到 102 億美元。
自主式人工智慧醫學影像是指能夠分析醫學影像、偵測異常、確定臨床觀察優先順序並輔助或獨立完成特定診斷解讀任務的人工智慧系統。診斷影像數量的不斷成長、放射科醫生的短缺以及對更快臨床決策日益成長的需求正在推動市場擴張。深度學習、電腦視覺、多模態人工智慧和醫學影像分析技術的進步正在提升診斷能力。對人工智慧放射學、自動化疾病篩檢和整合影像工作流程的持續投入,正為全球醫院、診斷中心、專科診所和遠距放射服務供應商創造龐大的商機。
診斷影像檢查工作量不斷增加,以及放射科專科醫生短缺。
診斷影像工作量的不斷增加和專業放射科醫生的短缺正在推動市場擴張。醫療機構正面臨X光、電腦斷層掃描(CT)、磁振造影(MRI)和其他診斷測試數量的激增。人工智慧影像解讀系統能夠識別異常情況、優先處理高優先病例並協助放射科醫生進行影像分析,從而提高工作流程效率。對早期疾病檢測和及時臨床干預日益成長的需求正在推動這些系統的應用。深度學習、影像識別和自動化診斷報告技術的進步進一步增強了醫療機構對智慧醫學影像解決方案的投資。
自主診斷的臨床效度要求和可靠性限制。
臨床檢驗要求和自主診斷可靠性方面的限制正在限制市場成長。醫學影像人工智慧系統必須在不同的掃描儀、影像方案、患者群體和臨床環境中保持表現的一致性。演算法錯誤、假觀察和漏診異常都可能引發病患安全問題。法規核准流程和臨床證據要求增加了開發成本和商業化時間。與影像歸檔和通訊系統 (PACS)、放射資訊系統 (RIS) 以及醫院工作流程的整合可能十分複雜。此外,如果沒有完善的課責機制,醫療機構可能對採用高度自主的解決方案有所顧慮。
在醫療服務不足的環境中推廣自主篩檢和人工智慧影像診斷。
在醫療資源匱乏的地區,自主篩檢和人工智慧影像診斷的推廣應用蘊藏著巨大的成長機會。能夠獨立評估特定影像觀察的人工智慧系統,可以為那些難以獲得專科醫生服務的地區提供診斷支援。胸部X光篩檢、眼科影像、乳房乳房攝影和急診診斷等領域的應用潛力巨大。對雲端成像平台、攜帶式診斷設備和遠端醫療基礎設施的持續投入,正在推動這些技術的普及應用。人工智慧開發商、醫療設備製造商和醫療服務提供者之間的夥伴關係,預計將進一步擴大自動化影像診斷的覆蓋範圍。
診斷法律責任風險、演算法偏見以及醫療人工智慧監管趨勢
診斷責任風險、演算法偏差以及不斷變化的醫療人工智慧法規威脅著市場擴張。自主成像系統在面對不熟悉的臨床情況、設備差異或患者群體時,可能會產生不準確的觀察。誤診和延誤治療決策可能導致法律問題和病人安全隱患。醫療機構必須解決監管合規、網路安全以及敏感醫學影像保護等問題。科技的快速發展也可能加劇競爭壓力和產品過時的風險。技術提供者必須展現強大的臨床檢驗、透明的效能監控機制以及充分的人工監督,才能維持市場信心。
新冠疫情加速了人們對人工智慧驅動的醫學影像技術的興趣,因為疫情增加了對快速乳房攝影篩檢評估、遠端放射學服務和高效診斷流程的需求。醫療機構考慮實施自動化影像判讀,以輔助分診並應對日益成長的影像工作量。然而,由於醫院預算限制、臨床營運中斷以及設備供應鏈挑戰,一些項目的實施被推遲。疫情凸顯了擴充性診斷基礎設施和遠端影像分析的價值。隨後,對醫療人工智慧、遠距放射學和數位成像平台的投資持續成長,從而推動了日益自動化的影像判讀技術的發展。
在預測期內,電腦斷層掃描(CT)領域預計將佔據最大的市場佔有率。
鑑於電腦斷層掃描 (CT) 在急診醫學、腫瘤學、心血管診斷和神經影像學等領域的廣泛應用,預計在預測期內,CT 領域將佔據最大的市場佔有率。 CT 掃描會產生複雜的影像資料集,而自動異常檢測、分割和臨床優先排序等技術能夠有效提升這些資料集的準確性。對快速評估中風、肺動脈栓塞、顱內出血和其他嚴重疾病的需求日益成長,推動了人工智慧 (AI) 的應用。與放射科工作流程的整合以及深度學習技術的進步,正在提高診斷成像的效率。對人工智慧驅動的急診影像技術的投資增加,進一步鞏固了該領域的市場地位。
在預測期內,全自動影像解譯領域預計將呈現最高的複合年成長率。
在預測期內,全自動影像判讀領域預計將呈現最高的成長率,這主要得益於人工智慧系統的進步,這些系統旨在執行特定診斷任務,而無需專家進行常規判讀。人們對自動篩檢、眼科診斷和標準化影像評估的興趣日益濃厚,這創造了新的機會。模型檢驗、影像品質評估和自動報告技術的改進正在推動該領域的發展。然而,這些技術的應用仍取決於臨床證據、監管部門的批准以及明確的操作條件。在醫療服務不足的地區擴展應用,有望加速該領域的成長。
在預測期內,北美預計將佔據最大的市場佔有率,這得益於其先進的醫學影像基礎設施、對醫學人工智慧的大量投資以及數位放射線系統的廣泛應用。在美國,醫療技術公司、研究機構、醫院網路和影像服務供應商正在推動人工智慧輔助影像解讀解決方案的普及,從而促進區域發展。影像工作量的增加以及放射科對更高效率日益成長的需求,是推動人工智慧技術應用的主要因素。完善的監管流程、研究經費以及人工智慧開發者與醫療機構的合作,都為人工智慧技術的商業化提供了支援。
在預測期內,亞太地區預計將呈現最高的複合年成長率,這主要得益於醫療基礎設施的不斷改進、診斷成像需求的成長以及人工智慧領域投資的持續增加。中國、印度、日本、韓國和澳洲正在推動醫學影像能力、數位醫療系統和人工智慧診斷服務的進步。龐大的患者數量和專業放射科醫生的短缺正在推動自動化影像解讀工具的普及。擴充性基礎設施、醫療技術新創公司以及政府的數位醫療舉措正在為該地區的發展提供支援。對高度可擴展的診斷篩檢和遠距醫療服務日益成長的需求預計將加速市場成長。
According to Stratistics MRC, the Global Autonomous AI Medical Imaging Interpretation Market is accounted for $2.8 billion in 2026 and is expected to reach $10.2 billion by 2034 growing at a CAGR of 17.7% during the forecast period. Autonomous AI Medical Imaging Interpretation involves artificial intelligence systems capable of analyzing medical images, detecting abnormalities, prioritizing clinical findings, and supporting or independently performing specified diagnostic interpretation tasks. Increasing diagnostic imaging volumes, radiologist shortages, and demand for faster clinical decisions are driving market expansion. Technological advancements in deep learning, computer vision, multimodal AI, and medical imaging analytics are improving diagnostic capabilities. Growing investments in AI-enabled radiology, automated disease screening, and integrated imaging workflows are creating significant opportunities across hospitals, diagnostic centers, specialty clinics, and teleradiology providers worldwide.
Increasing diagnostic imaging workloads and shortage of specialized radiology professionals
Increasing diagnostic imaging workloads and shortages of specialized radiology professionals are driving market expansion. Healthcare providers face rising volumes of X-ray, computed tomography, magnetic resonance imaging, and other diagnostic examinations. AI-powered interpretation systems can identify abnormalities, prioritize urgent cases, and assist radiologists with image analysis, improving workflow efficiency. Growing demand for early disease detection and timely clinical intervention encourages adoption. Advances in deep learning, image recognition, and automated diagnostic reporting further strengthen investment in intelligent medical imaging solutions across healthcare institutions.
Clinical validation requirements and limitations in autonomous diagnostic reliability
Clinical validation requirements and limitations in autonomous diagnostic reliability restrain market growth. Medical imaging AI systems must demonstrate consistent performance across different scanners, imaging protocols, patient populations, and clinical environments. Algorithmic errors, false-positive findings, and missed abnormalities can create patient safety concerns. Regulatory approval processes and clinical evidence requirements increase development costs and commercialization timelines. Integration with picture archiving and communication systems, radiology information systems, and hospital workflows can be complex. Healthcare organizations may also hesitate to deploy highly autonomous solutions without established accountability frameworks.
Expansion of autonomous screening and AI-enabled imaging interpretation in underserved healthcare settings
Expansion of autonomous screening and AI-enabled imaging interpretation in underserved healthcare settings presents significant growth opportunities. AI systems capable of independently assessing defined imaging findings can support diagnostic services where specialist availability is limited. Applications in chest X-ray screening, ophthalmic imaging, breast imaging, and emergency diagnostics offer considerable potential. Increasing investment in cloud-based imaging platforms, portable diagnostic devices, and telemedicine infrastructure encourages adoption. Partnerships between AI developers, medical equipment manufacturers, and healthcare providers are expected to expand access to automated imaging interpretation.
Diagnostic liability risks, algorithmic bias, and evolving medical AI regulations
Diagnostic liability risks, algorithmic bias, and evolving medical AI regulations threaten market expansion. Autonomous imaging systems may produce inaccurate findings when exposed to unfamiliar clinical conditions, equipment variations, or patient populations. Misdiagnosis and delayed treatment decisions can create legal and patient safety concerns. Healthcare organizations must address regulatory compliance, cybersecurity, and sensitive medical image protection. Rapid technological development may also increase competitive pressure and product obsolescence risks. Technology providers must demonstrate robust clinical validation, transparent performance monitoring, and appropriate human oversight to maintain market confidence.
The COVID-19 pandemic accelerated interest in AI-assisted medical imaging by increasing demand for rapid chest imaging assessment, remote radiology services, and efficient diagnostic workflows. Healthcare organizations explored automated image interpretation to support triage and manage increased imaging workloads. However, hospital budget constraints, clinical disruptions, and equipment supply chain challenges delayed certain deployments. The pandemic highlighted the value of scalable diagnostic infrastructure and remote image analysis. Subsequent investment in healthcare AI, teleradiology, and digital imaging platforms continues to support development of increasingly autonomous interpretation technologies.
The computed tomography (CT) segment is expected to be the largest during the forecast period
The computed tomography (CT) segment is expected to account for the largest market share during the forecast period due to extensive use in emergency medicine, oncology, cardiovascular diagnostics, and neurological imaging. CT examinations generate complex imaging datasets that benefit from automated abnormality detection, segmentation, and clinical prioritization. Increasing demand for rapid assessment of stroke, pulmonary embolism, intracranial hemorrhage, and other critical conditions supports AI adoption. Integration with radiology workflows and advances in deep learning improve interpretation efficiency. Growing investment in AI-assisted emergency imaging further strengthens the segment's market position.
The fully autonomous image interpretation segment is expected to have the highest CAGR during the forecast period
Over the forecast period, the fully autonomous image interpretation segment is predicted to witness the highest growth rate, supported by advances in AI systems designed to perform narrowly defined diagnostic tasks without routine specialist interpretation. Increasing interest in autonomous screening, ophthalmic diagnostics, and standardized imaging assessments creates opportunities. Improvements in model validation, image quality assessment, and automated reporting are supporting development. However, adoption remains dependent on clinical evidence, regulatory authorization, and clearly defined operating conditions. Expanding applications in underserved healthcare settings could accelerate segment growth.
During the forecast period, the North America is expected to hold the largest market share due to advanced medical imaging infrastructure, substantial investment in healthcare artificial intelligence, and widespread adoption of digital radiology systems. The United States leads regional development through medical technology companies, research institutions, hospital networks, and diagnostic imaging providers implementing AI-assisted interpretation solutions. Increasing imaging workloads and demand for radiology efficiency encourage adoption. Established regulatory pathways, research funding, and collaborations between AI developers and healthcare organizations support commercialization.
Over the forecast period, the Asia Pacific is anticipated to exhibit the highest CAGR, supported by expanding healthcare infrastructure, increasing diagnostic imaging demand, and growing investment in artificial intelligence. China, India, Japan, South Korea, and Australia are advancing medical imaging capabilities, digital healthcare systems, and AI-enabled diagnostic services. Large patient populations and shortages of specialized radiology professionals encourage adoption of automated interpretation tools. Expanding cloud infrastructure, healthcare technology startups, and government digital health initiatives support regional development. Increasing demand for scalable diagnostic screening and remote imaging services is expected to accelerate market growth.
Key players in the market
Some of the key players in the Autonomous AI Medical Imaging Interpretation Market include Aidoc Medical Ltd., Viz.ai, Inc., Qure.ai, Lunit, Inc., Harrison.ai, Gleamer, Oxipit, AZmed, Infervision, RapidAI, Brainomix Limited, HeartFlow, Inc., ScreenPoint Medical B.V., Digital Diagnostics, Inc., GE HealthCare Technologies Inc., Siemens Healthineers AG, Koninklijke Philips N.V., and Fujifilm Holdings Corporation.
In September 2026, Qure.ai reported that its clinical decision support system, Aira, had achieved Class IIb certification under the European Union Medical Device Regulation. The certification represents an important regulatory milestone for the company's AI-enabled clinical decision support capabilities. It also highlights the increasing emphasis on independent assessment, safety documentation, and regulatory compliance as medical AI platforms expand their clinical applications.
In April 2026, Sectra completed its acquisition of Oxipit, a developer of autonomous AI solutions for radiology. Oxipit developed ChestLink, a CE Class IIb-certified system designed to autonomously analyze selected chest X-ray examinations under defined clinical conditions. The acquisition strengthens Sectra's AI portfolio by combining Oxipit's autonomous interpretation technology with established enterprise imaging infrastructure.
In February 2026, Oxipit introduced CT Eye and MSK Eye, two CE-certified AI solutions expanding its medical imaging portfolio beyond chest radiography. CT Eye supports the identification of selected abnormalities in chest CT examinations, while MSK Eye extends AI-assisted analysis into musculoskeletal radiography. Both solutions are designed to integrate with existing radiology reporting workflows, supporting abnormality detection, examination prioritization, and reporting quality checks.
Note: Tables for North America, Europe, APAC, South America, and Rest of the World (RoW) Regions are also represented in the same manner as above.